Inotuzumab

Summary

Inotuzumab (CHEMBL4297558) is a phase-3 clinical-stage antibody; indicated across 1 condition including acute lymphoblastic leukemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 1 condition
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297558
Name	Inotuzumab
Type	Antibody
Max phase	3

Also known as: Besponsa, G5/44, G544, Inotuzumab, INOTUZUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acute lymphoblastic leukemia	3	MONDO:0004967	EFO:0000220

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03628053	PHASE3	WITHDRAWN	Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia
NCT06533748	PHASE2	RECRUITING	Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).